Biocytogen announced a global antibody licensing agreement with China compatriot BeOne on 10 July, building upon their existing partnership involving Biocytogen's RenMice fully human antibody platform. The deal grants BeOne rights to multiple antibody molecules discovered using Biocytogen's proprietary technology. Financial terms include upfront payments, development and regulatory milestones, commercial milestones and royalties on net sales.

Biocytogen CEO Dr. Yuelei Shen highlighted the strategic value of partnering with BeOne, a global oncology leader, to advance these candidates toward clinical development. The collaboration underscores Biocytogen's role in enabling innovative biologic drug discovery through its antibody generation platforms.